$10.01
-0.89 (-8.17%)
Open$10.56
Previous Close$10.90
Day High$10.73
Day Low$9.75
52W High$12.10
52W Low$4.52
Volume—
Avg Volume21.9K
Market Cap100.42M
P/E Ratio—
EPS$-0.06
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
-57.3% upside
Current
$10.01
$10.01
Target
$4.27
$4.27
$3.74
$4.27 avg
$6.64
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 30.72M | 26.91M | 25.83M |
| Net Income | -1,155,676 | -910,937 | 1.23M |
| Profit Margin | -3.8% | -3.6% | 4.8% |
| EBITDA | 2.36M | 1.96M | 1.46M |
| Free Cash Flow | — | — | 1.13M |
| Rev Growth | +14.2% | +14.2% | +0.8% |
| Debt/Equity | 0.34 | 0.34 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |